SiBone (NASDAQ:SIBN) Director Jeffrey Dunn Sells 20,000 Shares

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $21.28, for a total value of $425,600.00. Following the completion of the sale, the director owned 80,115 shares in the company, valued at approximately $1,704,847.20. This represents a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

SiBone Price Performance

SIBN stock traded down $2.57 during trading on Monday, hitting $17.87. The company had a trading volume of 1,671,465 shares, compared to its average volume of 746,750. The company has a fifty day moving average price of $18.93 and a two-hundred day moving average price of $17.11. SiBone has a fifty-two week low of $12.49 and a fifty-two week high of $21.89. The company has a market cap of $775.40 million, a P/E ratio of -35.04 and a beta of 0.69. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $48.66 million during the quarter, compared to analysts’ expectations of $46.67 million. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%. Equities research analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SIBN. Morgan Stanley raised their price target on SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Truist Financial increased their target price on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Needham & Company LLC raised their target price on SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Canaccord Genuity Group raised their price objective on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Institutional Investors Weigh In On SiBone

Several large investors have recently made changes to their positions in the stock. American Century Companies Inc. boosted its holdings in shares of SiBone by 22.5% during the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after acquiring an additional 521,683 shares during the period. Wellington Management Group LLP lifted its stake in shares of SiBone by 74.7% in the 3rd quarter. Wellington Management Group LLP now owns 853,266 shares of the company’s stock valued at $12,560,000 after acquiring an additional 364,897 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in shares of SiBone during the second quarter worth about $6,664,000. Impax Asset Management Group plc lifted its holdings in shares of SiBone by 48.2% during the third quarter. Impax Asset Management Group plc now owns 1,025,010 shares of the company’s stock worth $15,088,000 after purchasing an additional 333,249 shares during the period. Finally, Next Century Growth Investors LLC bought a new stake in shares of SiBone in the 2nd quarter valued at about $4,824,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.